Posted in | News | Nanomedicine | Nanobusiness

NanoViricides and Viroclinics Biosciences Ink Confidential Disclosure Agreement

NanoViricides, Inc. (the “Company”) reported today that it has signed a “confidential disclosure agreement” (“CDA”) with Viroclinics Biosciences, BV (“Viroclinics”), a spinoff of the Department of Viroscience at the Erasmus Medical Centre (“Erasmus”) in Rotterdam, the Netherlands.

The agreement will allow the scientists at Viroclinics to develop a specific proposal for the testing of different nanoviricides® , such as FluCide™, against viruses of mutual interest to both organizations.

Viroclinics is a virology contract research organization serving the biopharmaceutical community. Viroclinics provides preclinical as well as clinical development services for vaccines and antivirals. The ongoing, intimate interaction between scientists at Erasmus and Viroclinics staff yields a strong, flourishing platform to create and implement assays at the forefront of viroscience. Viroclinics participated in the discovery and characterization of the Middle East Respiratory Syndrome (MERS) Coronavirus in 2013 and SARS Coronavirus in 2003, attesting to its leadership position in the field.

NanoViricides, Inc. anticipates that we will be able to test and develop our drug candidates against influenzas, dengue, MERS Coronavirus, as well as rabies, with the help of Viroclinics. In particular, NanoViricides is interested in the testing of its lead broad-spectrum anti-influenza drug candidate FluCide against various influenza A strains including the highly lethal H5N1 and H7N9 viruses that pose a strong global public health threat.

Testing of nanoviricides antiviral drug candidates will be performed in a BSL2 or BSL3 facility at Viroclinics, as applicable. These facilities are designed to contain and enable the safe handling of organisms that can pose a significant threat to health. Executives from NanoViricides plan to visit the Rotterdam facility later this month to conclude the final research agreement.

About NanoViricides:

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoViricides, Inc. (2019, February 11). NanoViricides and Viroclinics Biosciences Ink Confidential Disclosure Agreement. AZoNano. Retrieved on April 18, 2024 from

  • MLA

    NanoViricides, Inc. "NanoViricides and Viroclinics Biosciences Ink Confidential Disclosure Agreement". AZoNano. 18 April 2024. <>.

  • Chicago

    NanoViricides, Inc. "NanoViricides and Viroclinics Biosciences Ink Confidential Disclosure Agreement". AZoNano. (accessed April 18, 2024).

  • Harvard

    NanoViricides, Inc. 2019. NanoViricides and Viroclinics Biosciences Ink Confidential Disclosure Agreement. AZoNano, viewed 18 April 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.